Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics

International Journal of Oncology

Volumn 43, Issue 3, 2013, Pages 895-902

  Cheng, Ka Wing ^a   Wong, Chi C ^a   Mattheolabakis, George ^a   Xie, Gang ^a   Huang, Liqun ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Cellular uptake; Curcumin; Lung cancer; Pharmacokinetics; Phospho sulindac

Indexed keywords

CURCUMIN; OXT 328; PHOSPHO SULINDAC; POLYSORBATE 80; SULINDAC; TURMERIC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; COLON CANCER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

EID: 84880626519     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1995     Document Type: Article

References (30)

1. Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G: Aspirin, salicylates and cancer. Lancet 373: 1301-1309, 2009.
2. Rothwell PM, Price JF, Fowkes FG, et al: Short-term effects of daily aspirin on cancer incidence, mortality and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612, 2012.
3. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379: 1591-1601, 2012.
4. Cheng KW, Mattheolabakis G, Wong CC, et al: Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol 41: 1199-1203, 2012.
5. Huang L, Mackenzie GG, Sun Y, et al: Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res 71: 7617-7627, 2011.
6. Mackenzie GG, Ouyang N, Xie G, et al: Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prev Res 4: 1052-1060, 2011.
7. Zhu C, Cheng KW, Ouyang N, et al: Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells 30: 2065-2075, 2012.
8. Zhu R, Cheng KW, Mackenzie G, et al: Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharm Res 29: 3090-3101, 2012.
9. Hanif R, Qiao L, Shiff SJ and Rigas B: Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 130: 576-584, 1997.
10. Kawamori T, Lubet R, Steele VE, et al: Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 59: 597-601, 1999.
11. Villegas I, Sanchez-Fidalgo S and de la Lastra CA: Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice. Mol Nutr Food Res 55: 259-267, 2011.
12. Su CC, Yang JS, Lu CC, et al: Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res 24: 189-192, 2010.
13. Dance-Barnes ST, Kock ND, Moore JE, et al: Lung tumor promotion by curcumin. Carcinogenesis 30: 1016-1023, 2009.
14. Giladi N, Kazanov D, Shpitz B, Aroch I, Kraus S and Arber N: Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin Investig Drugs 19: S117-S124, 2010.
15. Lee JY, Lee YM, Chang GC, et al: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PloS One 6: e23756, 2011.
16. Yin H, Guo R, Xu Y, et al: Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer. Acta Biochim Biophys Sin 44: 147-153, 2012.
17. Ganta S and Amiji M: Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6: 928-939, 2009.
18. Sung B, Kunnumakkara AB, Sethi G, et al: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8: 959-970, 2009.
19. Francois G and Katz JL: Nanoparticles and nanocapsules created using the Ouzo effect: spontaneous emulisification as an alternative to ultrasonic and high-shear devices. Chemphyschem 6: 209-216, 2005.
20. Galindo-Rodriguez S, Allemann E, Fessi H and Doelker E: Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion and nanoprecipitation methods. Pharm Res 21: 1428-1439, 2004.
21. Wong CC, Cheng KW, Xie G, et al: Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. J Pharmacol Exp Ther 340: 422-432, 2012.
22. Balimane PV, Han YH and Chong S: Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8: E1-E13, 2006.
23. Xie G, Nie T, Mackenzie GG, et al: The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. Br J Pharmacol 165: 2152-2166, 2012.
24. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
25. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II and III purified from Turmeric powder. Biochem Pharmacol 68: 2043-2052, 2004.
26. Shukla S, Zaher H, Hartz A, et al: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26: 480-487, 2009.
27. Wortelboer HM, Usta M, van der Velde AE, et al: Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16: 1642-1651, 2003.
28. Wortelboer HM, Usta M, van Zanden JJ, et al: Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds. Biochem Pharmacol 69: 1879-1890, 2005.
29. Li Y, Revalde JL, Reid G and Paxton JW: Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol 68: 603-610, 2011.
30. Rigas B and Shiff SJ: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases and the cell cycle. Their interactions in colon cancer. Adv Exp Med Biol 470: 119-126, 1999.